Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Stem Cell Research

Executive Summary. Y-27632 dihydrochloride is a cell-permeable, highly selective inhibitor of Rho-associated protein kinases ROCK1 and ROCK2 (IC₅₀ = 140 nM for ROCK1; K_i = 300 nM for ROCK2). It exhibits >200-fold selectivity over other kinases, including PKC, MLCK, cAMP-dependent protein kinase, and PAK, enabling precise studies of Rho/ROCK signaling (APExBIO). In research, Y-27632 disrupts Rho-mediated stress fiber assembly, modulates cell cycle progression, and enhances survival of stem cells and primary cells in vitro (Wang et al., 2025). It is soluble in DMSO, ethanol, and water at high concentrations (≥111.2 mg/mL, ≥17.57 mg/mL, and ≥52.9 mg/mL, respectively) and stable as a solid at ≤4°C. Y-27632 is a validated tool for translational research in cytoskeletal biology, stem cell viability, and cancer invasion models (see comparison).

Biological Rationale

Rho-associated protein kinases (ROCK1/2) are serine/threonine kinases that mediate signals from the small GTPase RhoA. These kinases regulate actin cytoskeleton organization, cellular contraction, and cell cycle transitions. Aberrant Rho/ROCK signaling drives tumor cell invasion, fibrotic responses, and impairs stem cell viability. Selective inhibition of ROCK1/2 enables researchers to dissect these pathways, revealing the distinct roles of cytoskeletal dynamics in cell proliferation, migration, and differentiation (Bio-protocol). Y-27632 dihydrochloride from APExBIO is widely used to probe these mechanisms with minimal off-target effects.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride acts by competitively binding the ATP-binding pocket of the catalytic domain of ROCK1 and ROCK2. This prevents substrate phosphorylation and downstream signaling. The compound's IC₅₀ for ROCK1 is approximately 140 nM, and its K_i for ROCK2 is 300 nM, confirming its high potency at sub-micromolar concentrations (APExBIO). It exhibits over 200-fold selectivity for ROCK1/2 relative to closely related kinases, such as protein kinase C (PKC), myosin light-chain kinase (MLCK), cAMP-dependent protein kinase (PKA), and p21-activated kinase (PAK). Inhibition of ROCK1/2 leads to decreased phosphorylation of downstream targets such as myosin light chain (MLC) and LIM kinase, resulting in reduced actin stress fiber formation, altered cell shape, and impaired cytokinesis. This mechanism underpins applications in cytoskeletal modulation, cell cycle studies, and stem cell survival (see mechanistic review).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM in biochemical kinase assays (APExBIO).
• Exhibits >200-fold selectivity versus PKC, MLCK, PKA, and PAK in side-by-side profiling (APExBIO).
• Reduces actin stress fiber formation in mammalian cells in vitro within 1–2 hours at 10–20 μM (cell imaging, DMSO as vehicle) (Wang et al., 2025).
• Enhances survival and clonal expansion of human pluripotent stem cells (hPSCs, hEPSCs) when added at 10 μM during cell dissociation and replating (Wang et al., 2025).
• Suppresses tumor invasion and metastasis in mouse models at 30 mg/kg/day intraperitoneal dosing for 7–14 days (FDX1-mRNA.com).
• Soluble at ≥111.2 mg/mL in DMSO, ≥52.9 mg/mL in water, and ≥17.57 mg/mL in ethanol; warming to 37°C or ultrasonic bath increases solubility (APExBIO).
• Stable as a solid below 4°C and as a DMSO stock at <-20°C for several months; aqueous solutions should be freshly prepared (APExBIO).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is indispensable in diverse research workflows:

• Cytoskeletal studies: Dissects actin-myosin contractility and stress fiber formation in epithelial, fibroblastic, and tumor cells.
• Stem cell research: Enhances survival of dissociated human pluripotent stem cells (hPSCs, hEPSCs), enabling efficient passaging and organoid formation (Wang et al., 2025).
• Cancer biology: Inhibits pro-invasive cytoskeletal remodeling and suppresses tumor invasion/metastasis in murine models.
• Cell cycle and cytokinesis: Used to study G1/S transition and block cytokinesis, revealing dependencies on ROCK activity.

This article extends and updates the mechanistic and experimental insights provided in this strategic review by focusing on quantitative benchmarks, solubility, and workflow integration.

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; it is highly selective for ROCK1/2 and does not directly inhibit PKC, MLCK, or PAK at working concentrations.
• Prolonged exposure (>48 hours) in stem cell cultures may cause adaptation or off-target effects—use only at recommended timeframes and concentrations (Bio-protocol).
• Solubility in aqueous buffers is limited; DMSO or ethanol stock solutions are preferred for consistent dosing.
• Not effective against all cell types—certain non-mammalian systems or highly differentiated tissues may show resistance to ROCK inhibition.
• Y-27632 is not a therapeutic drug; it is for research use only and not for clinical application.

Workflow Integration & Parameters

For in vitro studies, Y-27632 dihydrochloride is typically reconstituted at 10–20 mM in DMSO, filtered, aliquoted, and stored at <-20°C. For use, dilute immediately before application to a final concentration of 5–20 μM in culture media. Enhanced solubility can be achieved by heating to 37°C or using ultrasonic baths. In stem cell research, addition of 10 μM Y-27632 during cell dissociation and replating improves viability and colony formation (Wang et al., 2025). For in vivo work, dosing regimens such as 30 mg/kg/day intraperitoneally have been validated for inhibition of tumor invasion in mice (FDX1-mRNA.com).

Refer to the Y-27632 dihydrochloride product page at APExBIO for full solubility data, storage recommendations, and handling instructions. This article clarifies recent advances and practical details beyond the scope of prior protocol-focused summaries.

Conclusion & Outlook

Y-27632 dihydrochloride (A3008, APExBIO) is a gold-standard, highly selective ROCK1/2 inhibitor validated for cytoskeletal modulation, stem cell viability, and tumor invasion studies. Its potency, selectivity, and robust solubility enable reproducible research in cell and molecular biology. Future applications include advanced organoid workflows, drug screening, and regenerative medicine models. For further reading on strategic and translational contexts, see this translational perspective, which complements the technical orientation of this article.